- Samsung Biologics has signed a $262 million manufacturing agreement with an undisclosed European pharmaceutical company, extending production commitments through 2033.
- Production will take place at the company’s Songdo site in South Korea, bringing its cumulative contract value to more than $21.9 billion.
Samsung Biologics, a contract development and manufacturing organization (CDMO) headquartered in Incheon, South Korea, has signed a $262 million manufacturing agreement with an undisclosed European pharmaceutical company. The agreement extends production commitments through 2033, with manufacturing to take place at Samsung Biologics’ Songdo site in South Korea. The client and product details were not disclosed due to confidentiality provisions.
The agreement brings Samsung Biologics’ cumulative contract value to more than $21.9 billion. The company said demand for long-term manufacturing capacity remains strong across its network.
Samsung Biologics currently operates 845,000 liters of manufacturing capacity across South Korea and the United States. This includes 785,000 liters at its Songdo site and 60,000 liters at its facility in Rockville, Maryland. The company also has land secured for Bio Campus III in South Korea as it plans additional manufacturing capacity and capabilities.
The CDMO is also pursuing further expansion through its longer-term manufacturing strategy. In August, Samsung Biologics announced a KRW 3 trillion (approximately $2.2 billion) rights offering, with KRW 2.71 trillion allocated toward the planned acquisition of PolyPeptide Group and approximately KRW 290 billion designated for expansion of Bio Campus II.
